Skip to content

News

Random Mutations Play Major Role in Cancer

Random Mutations Play Major Role in Cancer

(April 7, 2017) A major new study published in Science claims that the reason why many people get cancer is simply just bad luck. It’s normal for people to seek … Continued

Niraparib Approved for Maintenance Treatment of Ovarian Cancer

Niraparib Approved for Maintenance Treatment of Ovarian Cancer

(March 28, 2017) The U.S. Food and Drug Administration approved niraparib (ZEJULA, TESARO, Inc.), poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, … Continued

Research Updates from 2017 SGO Annual Meeting

Research Updates from 2017 SGO Annual Meeting

(March 23, 2017) OCRFA staff and volunteers recently attended the Society of Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer, held March 11-14, 2017 in Maryland. Every year women’s cancer … Continued

Rucaparib Extends PFS in Ovarian Cancer

Rucaparib Extends PFS in Ovarian Cancer

(February 3, 2017) Results from the ARIEL2 trial, funded in part by OCRFA’s grant to the Stand Up to Cancer Ovarian Cancer Dream Team, were recently published in The Lancet. … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.